AstraZeneca PLC AZNCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZNCF is a good fit for your portfolio.
News
-
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca
-
AstraZeneca Launches Health-Tech Business Evinova — Update
-
AstraZeneca Launches Health-Tech Business Evinova to Support Clinical Studies
-
Trending: AstraZeneca Hikes Forecasts and Makes a $2 Billion Licensing Deal
-
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
-
AstraZeneca Shares Rise After Guidance Increase
-
AstraZeneca Agrees on Licensing Deal for Obesity Treatment
-
AstraZeneca Raises Core EPS Guidance Despite Profit Miss — Update
Trading Information
- Previous Close Price
- $128.52
- Day Range
- $125.41–126.50
- 52-Week Range
- $120.60–153.10
- Bid/Ask
- $125.25 / $130.50
- Market Cap
- $196.07 Bil
- Volume/Avg
- 1,656 / 3,397
Key Statistics
- Price/Earnings (Normalized)
- 17.90
- Price/Sales
- 4.46
- Dividend Yield
- 2.25%
- Dividend Yield (Forward)
- 2.25%
- Total Yield
- 2.25%
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 83,500
- Website
- https://www.astrazeneca.com
Competitors
Valuation
|
Metric
|
AZNCF
|
PFE
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.90 | 10.20 | 73.30 |
Price/Book Value | 5.36 | 1.71 | 49.55 |
Price/Sales | 4.46 | 2.44 | 16.50 |
Price/Cash Flow | 20.22 | 8.58 | 77.25 |
Price/Earnings
AZNCF
PFE
LLY
Financial Strength
|
Metric
|
AZNCF
|
PFE
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.60 | 1.90 | 0.58 |
Current Ratio | 0.79 | 2.38 | 1.05 |
Interest Coverage | 5.27 | 6.05 | 14.87 |
Quick Ratio
AZNCF
PFE
LLY
Profitability
|
Metric
|
AZNCF
|
PFE
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 61.67% | 8.04% | 10.19% |
Return on Equity (Normalized) | 162.15% | 16.96% | 49.42% |
Return on Invested Capital (Normalized) | 91.05% | 11.79% | 19.29% |
Return on Assets
AZNCF
PFE
LLY
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
LLY
| Eli Lilly and Co | Dnhd | $556.0 Bil | |
JNJ
| Johnson & Johnson | Qcnyh | $382.5 Bil | |
MRK
| Merck & Co Inc | Pxjv | $266.2 Bil | |
ABBV
| AbbVie Inc | Tykbxgh | $254.5 Bil | |
RHHBY
| Roche Holding AG ADR | Vcd | $227.0 Bil | |
NVS
| Novartis AG ADR | Jgd | $202.7 Bil | |
AZN
| AstraZeneca PLC ADR | Pktb | $202.0 Bil | |
PFE
| Pfizer Inc | Gpsp | $165.3 Bil | |
AMGN
| Amgen Inc | Jgr | $145.9 Bil | |
SNY
| Sanofi SA ADR | Nhzfv | $119.1 Bil |